Autopsy report · NCT01666600

NOA-12: BIBF1120 and R-RT in Glioblastoma

“Interim Analysis for Feasibility”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 5 years 1 month before it stopped.
• 63 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Prof. Dr. Wolfgang Wick

Sponsor type

University, hospital or other

Conditions

Glioblastoma Multiforme

Interventions

BIBF 1120; radiotherapy

Participants

63

Sites

2

Countries

Germany

Trials that died the same way

• The Role of Post-traumatic Inhibition of the Innate and Adaptive Immune System in the Development of Infectious Complications in Severely Injured Patients
  “Interim analysis provided enough data” (67% match in meaning)
• Asymptomatic Leishmania Infection in HIV Patients
  “Aim to assess feasibility achieved, larger project starting earlier than anticipated” (66% match in meaning)
• Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
  “Pending Interim Analysis” (65% match in meaning)
• Hypothermia After In-hospital Cardiac Arrest
  “interim analysis with stopping for futility” (64% match in meaning)
• Liberty Analyzer WBC System: Reference Interval Study
  “For interim analysis.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.